Related Experiment Video
Updated: Mar 15, 2026

06:34
Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
Published on: June 2, 2023
1.9K
Brain Stimulation in Alzheimer's Disease
Itzhak Fried1,2
1Department of Neurosurgery, David Geffen School of Medicine, and Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA.
Journal of Alzheimer'S Disease : JAD
|August 29, 2016
Summary
Deep brain stimulation (DBS) for Alzheimer's disease (AD) may slow cognitive decline in older patients but risks worsening it in younger ones. Further research is needed to understand DBS effects in AD.
Area of Science:
- Neuroscience
- Neurology
- Medical Research
Background:
- Deep brain stimulation (DBS) is effective for Parkinson's motor symptoms.
- Alzheimer's disease (AD) presents significant cognitive challenges.
- The efficacy of DBS for cognitive symptoms in AD is under investigation.
Purpose of the Study:
- To evaluate the impact of deep brain stimulation of the fornix on cognitive symptoms in Alzheimer's disease (AD).
- To assess the safety and efficacy of DBS in different age groups within the AD patient population.
Main Methods:
- A multi-center, prospective, randomized study involving deep brain stimulation of the fornix in Alzheimer's disease patients.
- Analysis of cognitive decline and clinical course based on patient age and stimulation parameters.
Main Results:
- Deep brain stimulation showed a modest slowing of cognitive decline in a subset of patients older than 65.
- Younger patients (<65) experienced an exacerbation of cognitive decline with deep brain stimulation.
- The study highlights age-dependent differential responses to DBS in AD.
Conclusions:
- Deep brain stimulation of the fornix may offer potential benefits for cognitive symptoms in older AD patients.
- The risk of worsening cognitive decline in younger AD patients necessitates caution and further investigation.
- There is a critical need for more research, including animal models and adaptive patient studies, to elucidate AD pathophysiology and optimize DBS parameters.
Related Concept Videos
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

